Test Concentration | Lot 2B | Lot 3A | Lot 3B | |||||||
---|---|---|---|---|---|---|---|---|---|---|
R2 | Emax | EC50 | R2 | Emax | EC50 | R2 | Emax | EC50 | ||
Test Compounds | μM | Fold | μM | Fold | μM | Fold | μM | |||
Rifampicin | 0.01– 50 | 0.98 | 22 | 0.36 | 0.96 | 28 | 0.27 | 0.98 | 26 | 0.52 |
Phenytoin | 0.6–120 | 1.00 | 23 | 15 | 1.00 | 38 | 16 | 0.99 | 35 | 23 |
Carbamazepine | 0.23–500 | 1.00 | 16 | 108 | 1.00 | 10 | 65 | 0.98 | 14 | 53 |
Phenobarbital | 0.91–2000 | 1.00 | 110 | 558 | 1.00 | 135 | 728 | 1.00 | 73 | 775 |
Terbinafine | 0.05–100 | 1.00 | 20 | 3.6 | 1.00 | 24 | 2.2 | 0.99 | 21 | 2.7 |
Sulfinpyrazone | 0.09–200 | 1.00 | 31 | 23 | 0.98 | 53 | 28 | 0.98 | 38 | 32 |
Probenecid | 0.13–300 | 1.00 | 25 | 187 | 1.00 | 26 | 176 | 1.00 | 22 | 195 |
Pioglitazone | 0.006–12.5 | 0.99 | 33 | 3.3 | 0.99 | 31 | 2.3 | 0.98 | 15 | 2.0 |
Dexamethasone | 0.11–250 | 1.00 | 32 | 139 | 1.00 | 53 | 117 | 1.00 | 29 | 134 |
Rosiglitazone | 0.05–100 | 0.99 | 49 | 3.8 | 1.00 | 85 | 4.3 | 1.00 | 95 | 4 |
Omeprazole | 0.05–100 | 1.00 | 24 | 13 | 1.00 | 45 | 23 | 1.00 | 27 | 13 |
Clotrimazole | 0.005–10 | 1.00 | 16 | 0.58 | 0.99 | 18 | 0.35 | 1.00 | 17 | 0.33 |
Nifedipine | 0.05–100 | 1.00 | 28 | 5.6 | 0.99 | 40 | 6.6 | 0.99 | 27 | 3.5 |
Quinidine | 0.11–250 | NA | 1.0 | NA | NA | 2.0 | NA | NI | 1.12 | NI |
Flumazenil | 0.023–50 | NI | NI | NI | NI | NI | NI | NI | NI | NI |
Primaquine | 0.05–40 | NI | NI | NI | NI | NI | NI | NI | NI | NI |
Methotrexate | 0.009–20 | NI | NI | NI | NI | NI | NI | NI | NI | NI |
Digoxin | 0.0002–0.2 | NI | NI | NI | NI | NI | NI | NI | NI | NI |
NA, not able to conduct curve fitting to obtain EC50 and Emax due to no concentration-dependent response curve was obtained (only observed maximum fold induction is reported); NI, no induction observed at tested concentration.